scholarly journals Algae as a Source of Bioactive Compounds to Prevent the Development of Type 2 Diabetes Mellitus

2021 ◽  
Vol 28 ◽  
Author(s):  
Jelena B. Popović-Djordjević ◽  
Jelena S. Katanić Stanković ◽  
Vladimir Mihailović ◽  
A.G. Pereira ◽  
P. Garcia-Oliveira ◽  
...  

: Type 2 diabetes mellitus is a complicated metabolic disorder characterized by hyperglycemia and glucose intolerance. It is considered as a new pandemic whose control is creating numerous challenges. Although many of the measures are based on improving life habits, diet is also of vital importance due to bioactive compounds present in food. In this regard, several raw materials have been investigated whose bioactivities seem to slow the progression of this disease. Within these matrices there are algae of importance, such as brown algae, showing to have beneficial effects on glycemic control. These evidences are increasing every day due to the development of cell or animal models which leads to the conclusion that bioactive compounds may have direct effects on decreasing hyperglycemia, enhancing insulin secretion and preventing formation of amyloid plaques. Type 2 diabetes mellitus is a complicated metabolic disorder characterized by hyperglycemia and glucose intolerance. It is considered as a new pandemic whose control is creating numerous challenges. Although many of the measures are based on improving life habits, diet is also of vital importance due to bioactive compounds present in food. In this regard, several raw materials have been investigated whose bioactivities seem to slow the progression of this disease. Within these matrices there are algae of importance, such as brown algae, showing to have beneficial effects on glycemic control. These evidences are increasing every day due to the development of cell or animal models which leads to the conclusion that bioactive compounds may have direct effects on decreasing hyperglycemia, enhancing insulin secretion and preventing formation of amyloid plaques.

2008 ◽  
Vol 25 (3) ◽  
pp. 333-340 ◽  
Author(s):  
N. P. E. Kadoglou ◽  
F. Iliadis ◽  
N. Angelopoulou ◽  
D. Perrea ◽  
C. D. Liapis ◽  
...  

2020 ◽  
Vol 11 (7) ◽  
pp. 5749-5767
Author(s):  
Huicui Liu ◽  
Min Zhang ◽  
Qingyu Ma ◽  
Baoming Tian ◽  
Chenxi Nie ◽  
...  

Resistant starch (RS) is well known to prevent type 2 diabetes mellitus (T2DM) and obesity.


2018 ◽  
Vol 62 (2) ◽  
Author(s):  
Carlos Kornhauser ◽  
Gloria Barbosa-Sabanero ◽  
Noemí Gutierrez-Romero ◽  
Myrna Sabanero ◽  
Elva L. Perez-Luque ◽  
...  

The beneficial effects of a short period of Telmisartan administration were successfully assessed trough pentosidine urinary levels (uPen) and urinary podocyte excretion (UPE), in type 2 diabetes mellitus (DM2) patients. Patients with podocyturia received Telmisartan treatment (80 mg/day) for two months.  uPen were quantified pre and post treatment using HPLC with fluorimetric detection and in-lab synthesized standard. Immunofluorescence method for podocalyxin was used to evaluate urinary excretion of podocytes. uPen and UPE significantly decrease after treatment (p<0.01255 and p<0.005 respectively), as well as serum total cholesterol and LDL levels (p<0.001). These results suggest that podocyte protection by Telmisartan even in the face of deficient metabolic control could be an important matter in the prevention and progression of diabetic nephropathy. This study also strengthens evidence of the promising role of pentosidine as prognostic and diagnostic markers in diabetic nephropathy


Background: The oral administration of Astaxanthin may decrease depression symptoms and improved cognitive function through its beneficial effects on inflammation, and oxidative stress. Objective: This study was designed to assess whether Astaxanthin supplementation can reduce symptoms of depression and increase MMSE score in patients with Type 2 Diabetes Mellitus. Methods: This randomized, double-blind, placebo-controlled clinical trial was performed in 44 patients between 30 and 60 y of age with a diagnosis of type 2 diabetes. Patients were randomly assigned to receive either a single capsule of 8 mg of Astaxanthin /day (n = 22) or placebo (n = 22) for 8 wk. The primary [Beck Depression Inventory (BDI), which examines depressive symptoms] and secondary (Mini-Mental State Examination (MSSE) score, which evaluates cognitive function) outcomes were assessed. Results: After 8 week of intervention, Mini-Mental State Examination baseline score was significantly improved only in the group treated with Astaxanthin, during study (p < 0.01). But no significant reduction in the Beck Depression Inventory (BDI) was observed in both group. Conclusion: Overall, Astaxanthin supplementation of patients with diabetes for 8 weeks had beneficial effects on the MMSE score. Key words: Astaxanthin, Cognitive function Depression


Sign in / Sign up

Export Citation Format

Share Document